165 related articles for article (PubMed ID: 7689130)
21. Immunological classification of chronic myeloid leukemia distinguishes chronic phase, imminent blastic transformation, and acute lymphoblastic leukemia.
Schmetzer HM; Gerhartz HH
Exp Hematol; 1997 Jun; 25(6):502-8. PubMed ID: 9197328
[TBL] [Abstract][Full Text] [Related]
22. Expression of KL-6 antigen on leukemia cells of a patient with chronic myelocytic leukemia in blastic phase.
Takubo T; Fujino H; Hino M; Yamane T; Ohta K; Koh KR; Kumura T; Hashimoto S; Nakao T; Nakamae H; Aoyama Y; Nishiki S; Kinoshita Y; Kamitani T; Tatsumi N; Hojo S; Fujita J
Haematologia (Budap); 2001; 31(2):173-6. PubMed ID: 11583030
[No Abstract] [Full Text] [Related]
23. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
24. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte colony-stimulating factor receptors on human acute leukemia: biphenotypic leukemic cells possess granulocyte colony-stimulating factor receptors.
Shimoda K; Okamura S; Harada N; Ikematsu W; Kondo S; Kawasaki C; Tanaka T; Etou T; Akashi K; Okamura T
Cancer Res; 1992 Jun; 52(11):3052-5. PubMed ID: 1534271
[TBL] [Abstract][Full Text] [Related]
26. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
[TBL] [Abstract][Full Text] [Related]
27. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Handa H; Motohashi S; Isozumi K; Komatsumoto S; Nara M
Acta Haematol; 2002; 108(1):47-52. PubMed ID: 12145468
[TBL] [Abstract][Full Text] [Related]
28. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.
Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA
Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure.
Maciejewski JP; Anderson S; Katevas P; Young NS
Br J Haematol; 1994 Jun; 87(2):227-34. PubMed ID: 7524621
[TBL] [Abstract][Full Text] [Related]
30. Basophilic myeloblasts: a clue for CML blast phase.
Liu H
Blood; 2021 May; 137(20):2852. PubMed ID: 34014290
[No Abstract] [Full Text] [Related]
31. CD4 predicts nonlymphocytic lineage in acute leukemia. Insights from analysis of 125 cases using two-color flow cytometry.
Larson RS; McCurley TL
Am J Clin Pathol; 1995 Aug; 104(2):204-11. PubMed ID: 7543728
[TBL] [Abstract][Full Text] [Related]
32. The c-kit molecule and the surface immunophenotype of human acute leukemia.
Kubota A; Okamura S; Shimoda K; Harada M; Niho Y
Leuk Lymphoma; 1994 Aug; 14(5-6):421-8. PubMed ID: 7529077
[TBL] [Abstract][Full Text] [Related]
33. [Blast crisis of chronic myelogenous leukemia with blasts expressing both immature B lymphocyte- and myelomonocyte-associated antigens and differentiating into basophils in vitro].
Utsunomiya Y; Iwamasa K; Yasukawa M; Tamai T; Shiosaka T; Bando S
Rinsho Ketsueki; 1990 Jul; 31(7):1017-21. PubMed ID: 2214182
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia possibly producing thrombopoietic factor(s).
Fujita A; Matsuoka M; Shimonaka Y; Imai N; Asano S
Jpn J Clin Oncol; 1993 Dec; 23(6):366-72. PubMed ID: 7506802
[TBL] [Abstract][Full Text] [Related]
35. Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
Wang HY; Tzachanis D
Blood; 2020 Aug; 136(9):1112. PubMed ID: 32853380
[No Abstract] [Full Text] [Related]
36. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
38. B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.
Akashi K; Taniguchi S; Nagafuji K; Harada M; Shibuya T; Hayashi S; Gondo H; Niho Y
Leuk Res; 1993 Jul; 17(7):549-55. PubMed ID: 8326735
[TBL] [Abstract][Full Text] [Related]
39. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody anti-MPO is useful in recognizing minimally differentiated acute myeloid leukaemia.
Praxedes MK; De Oliveira LZ; Pereira Wda V; Quintana IZ; Tabak DG; De Oliveira MS
Leuk Lymphoma; 1994 Jan; 12(3-4):233-9. PubMed ID: 8167554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
